FDA approves pembrolizumab with chemotherapy for …
WEB6 days ago · Patients were randomized (1:1) to receive either pembrolizumab for up to 2 years in combination with pemetrexed and platinum-based chemotherapy for up to 6 cycles (n=222) or pemetrexed and ...
New Pembrolizumab Data Presented at ESMO Show Promise in a …
WEB4 days ago · Multiple new trial results have been presented at the European Society for Medical Oncology (ESMO) Congress 2024 supporting the use of pembrolizumab (Keytruda; Merck) in a variety of cancer types, including breast cancer, melanoma, hepatocellular carcinoma, and cervical cancer. Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy ...
Pembrolizumab improves outcomes in high-risk bladder cancer
WEBSep 16, 2024 · NCI Press Office. 240-760-6600. Adjuvant pembrolizumab helps people with muscle-invasive bladder cancer remain cancer-free longer than observation alone. Credit: Terese Winslow/National Cancer Institute. Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk ...
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before …
WEBSep 15, 2024 · RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first-time presentation of overall survival (OS) results from the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single ...
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
WEBJul 27, 2021 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Save. July 27, 2021 6:30 am ET.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
WEBJul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
WEBOn October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell …
WEBApr 17, 2024 · Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial.
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBOct 13, 2021 · KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.